2030 goals and drug donations for lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases and trachoma
| Disease | WHO 2030 goal11 | Coverage achieved in 201912 | Drug donor and donation11 |
| Lymphatic filariasis (elephantiasis) | Elimination as a public health problem (infection sustained below transmission assessment survey thresholds for at least 4 years after stopping mass drug administration; availability of essential package of care in all areas of known patients) validated in 58 (81%) countries | 62.7% | Eisai: up to 400 million diethylcarbamazine (DEC) tablets per year until elimination Merck Sharp & Dohme: unlimited ivermectin in settings co-endemic with onchocerciasis (recently expanded to include up to 250 million tablets per year through 2025 for communities eligible for the triple-therapy mass drug administration regimen of ivermectin, DEC and albendazole) GlaxoSmithKline: up to 600 million albendazole tablets annually until elimination |
| Onchocerciasis (river blindness) | Elimination of transmission verified in 12 (31%) countries | 62.8% | Merck Sharp & Dohme: ivermectin for as long as needed |
| Schistosomiasis (bilharzia) | Elimination as a public health problem (currently defined as <1% proportion of heavy intensity Schistosoma infections) validated in 78 (100%) countries | SAC: 59.3% Adults: 14.3% | Merck KGaA: up to 250 million praziquantel tablets annually for an unlimited period |
| Soil-transmitted helminthiases (intestinal helminths) | Elimination as a public health problem (<2% proportion of soil-transmitted helminth infections of moderate and heavy intensity due to Ascaris lumbricoides, Trichuris trichiura, Necator americanus and Ancylostoma duodenale) validated in 96 (96%) countries | Pre-SAC: 36.8% SAC: 57.8% | Johnson & Johnson: 200 million mebendazole tablets annually for SAC until 2025 GlaxoSmithKline: 200 million albendazole tablets annually for SAC |
| Trachoma | Elimination as a public health problem ((i) a prevalence of trachomatous trichiasis ‘unknown to the health system’ of <0.2% in ≥15-year-olds in each formerly endemic district; (ii) a prevalence of trachomatous inflammation—follicular in children aged 1–9 years of <5% in each formerly endemic district; and (iii) written evidence that the health system is able to identify and manage incident cases of trachomatous trichiasis, using defined strategies, with evidence of appropriate financial resources to implement those strategies) validated in 64 (100%) countries | 57.2% | Pfizer: unlimited quantity of azithromycin until 2025 |
Pre-SAC, Pre-school-age children; SAC, School-age children.